Relmada Phase 3 Reliance II Trial Called Futile at Interim Analysis

 The DMC did not identify any new safety concerns

Relmada to evaluate potential next steps for the REL-1017 program

Relmada to continue to focus on the development of REL-P11 for metabolic disease

Relmada is well capitalized with approximately $54.1 million in cash and cash equivalents as of September 30, 2024

https://www.globenewswire.com/news-release/2024/12/04/2991367/0/en/Relmada-Therapeutics-Reports-That-Data-Monitoring-Committee-DMC-Assessment-Indicates-That-the-Phase-3-Reliance-II-Trial-is-Futile-at-its-Interim-Analysis-and-is-Unlikely-to-Meet-th.html